832735-56-5

Basic information

• Product Name: 4-broMo-2-(difluoroMethoxy)pyridine
• Synonyms: 4-broMo-2-(difluoroMethoxy)pyridine;Pyridine,4-bromo-2-(difluoromethoxy)-
• CAS NO: 832735-56-5
• Molecular Formula: C₆H₄BrF₂NO
• Molecular Weight: 224.0028664
• Mol File: 832735-56-5.mol

Chemical Properties

• Boiling Point: 198.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.670±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0?+-.0.10(Predicted)
• CAS DataBase Reference: 4-broMo-2-(difluoroMethoxy)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-2-(difluoroMethoxy)pyridine(832735-56-5)
• EPA Substance Registry System: 4-broMo-2-(difluoroMethoxy)pyridine(832735-56-5)

Safety Data

• Hazardous Substances Data: 832735-56-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-Bromo-2-(difluoromethoxy)pyridine is used as a building block in the synthesis of various pharmaceuticals and agrochemicals. Its ability to act as a nucleophile and form carbon-carbon bonds allows for the creation of diverse and complex molecular structures, contributing to the development of new drugs and pesticides.
Used in OLEDs (Organic Light-Emitting Diodes) Industry:
4-Bromo-2-(difluoromethoxy)pyridine is utilized in the development of OLEDs due to its unique electronic properties. Its incorporation into the organic materials used in OLEDs can enhance their performance, leading to improved display technologies and lighting solutions.
Used as an Intermediate in Chemical Compound Production:
4-broMo-2-(difluoroMethoxy)pyridine serves as an intermediate in the production of various chemical compounds. Its versatile chemical structure allows for further functionalization and modification, enabling the synthesis of a wide range of specialized chemicals for different applications.
Used in Antifungal Applications:
4-Bromo-2-(difluoromethoxy)pyridine has been studied for its potential biological activities, including its use as a potential antifungal agent. Its ability to inhibit fungal growth and disrupt fungal cell functions makes it a promising candidate for the development of new antifungal drugs and treatments.

Upstream product

• 36953-37-4 4-bromo-2(1H)-pyridinone 
• 1895-39-2 sodium chlorodifluoroacetate 
• 76-04-0 2-chloro-2,2-difluoroacetic acid 
• 115262-01-6 [bromo(difluoro)methyl]-trimethyl-silane 

Downstream Products

• 1227184-45-3 5-(2-(Difluoromethoxy)pyridin-4-yl)-5-(3-(3-fluoropropoxy)phenyl)-5H-pyrrolo[3,4-b]pyridin-7-amine 
• 1628116-87-9 2-difluoromethoxy-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine 

Relevant articles and documents

Chemoselective N- And O-Difluoromethylation of 2-Pyridones, Isoquinolinones, and Quinolinones with TMSCF2Br

An operationally simple protocol for direct N- and O-difluoromethylation of 2-pyridones, quinolinones, and isoquinolinones using commercially available TMSCF2Br is disclosed. The chemoselectivity is modulated by simple variations in temperature, solvent,

NOVEL COMPOUNDS

The present invention relates to substituted 5-membered nitrogen containing heteroaryl compounds, such as sulfonyl triazoles, where the heteroaryl ring is further substituted, optionally via a linking group such as -NH-, with a cyclic group which in turn is substituted at the α-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES FOR TREATING NEUROLOGICAL AND NEURODEGENERATIVE DISEASES

The present invention provides, in part, compounds of Formula (I): or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N- oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4- associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES

The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N- oxide, wherein: (R1)a, (R2)b, (R3)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4- associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS

The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.

NEW COMPOUNDS 575

The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.